Eloxx Pharmaceuticals (NASDAQ: EXAS) and EXACT Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.
This is a summary of recent recommendations and price targets for Eloxx Pharmaceuticals and EXACT Sciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Eloxx Pharmaceuticals and EXACT Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Eloxx Pharmaceuticals and EXACT Sciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eloxx Pharmaceuticals||$80,000.00||6,318.27||-$21.21 million||N/A||N/A|
|EXACT Sciences||$265.99 million||22.99||-$114.39 million||($0.99)||-50.32|
Eloxx Pharmaceuticals has higher earnings, but lower revenue than EXACT Sciences.
Institutional and Insider Ownership
87.2% of EXACT Sciences shares are held by institutional investors. 44.0% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of EXACT Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Eloxx Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, EXACT Sciences has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Eloxx Pharmaceuticals beats EXACT Sciences on 7 of the 12 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.